Unbuzzd Wellness Launches $5 Million Regulation D Offering to Fuel Growth and IPO Ambitions

Unbuzzd Wellness Inc., a portfolio company of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM), has announced the launch of a Regulation D 506(c) offering aimed at raising up to $5 million. This strategic move is designed to fund the company's growth initiatives and advance its preparations for a potential initial public offering (IPO). Notably, this capital raise includes an anti-dilution provision that safeguards Quantum BioPharma's 25% ownership stake in Unbuzzd until the beverage company achieves a $1 billion valuation.

Unbuzzd is the creator of unbuzzd(TM), a beverage formulated to accelerate alcohol metabolism, restore mental clarity, and mitigate hangover symptoms. For this offering, Unbuzzd has partnered with MZ Digital and Dealmaker, enabling the campaign to accept both traditional and cryptocurrency investments. According to CEO John Duffy, the funds raised will bolster the company's direct-to-consumer, distributor, and retail expansion efforts. Board Co-Chair Gerry David emphasized that this partnership is a pivotal step toward positioning Unbuzzd for a future IPO.

Quantum BioPharma, the parent company, is a biopharmaceutical firm focused on developing innovative solutions for neurodegenerative and metabolic disorders, including alcohol misuse. Through its subsidiary, Lucid Psycheceuticals Inc., Quantum BioPharma is advancing Lucid-MS, a patented compound with potential applications in treating multiple sclerosis by addressing myelin degradation. The company's strategic investments, including its stake in Unbuzzd, underscore its commitment to fostering groundbreaking biotech and wellness solutions.

For more details on Quantum BioPharma's initiatives and updates, interested parties can visit https://ibn.fm/QNTM. Additional information about Unbuzzd and its offerings is available at https://www.unbuzzd.com.